Download PDF
Thromb Haemost 2010; 104(05): 867-874
DOI: 10.1160/TH10-01-0058
Theme Issue Article
Schattauer GmbH

Studies on Fletcher trait and Fitzgerald trait

A rare chance to disclose body’s defense reactions against injury
Hidehiko Saito
1   Nagoya Central Hospital, Nagoya, Japan
› Author Affiliations
Further Information

Publication History

Received: 22 January 2010

Accepted after minor revision: 06 April 2010

Publication Date:
24 November 2017 (online)

Also available at
    Permissions and Reprints

Summary

The way by which contact of blood with foreign surface accelerates clotting has been elucidated from the discovery of four rare disorders of blood coagulation; Hageman trait, plasma thromboplastin antecedent (PTA) deficiency, Fletcher trait, and Fitzgerald trait. Interestingly, it was unexpectedly found that Fletcher factor is plasma prekallikrein and Fitzgerald factor is high-molecular-weight kininogen; components of the kinin-generating system, thus disclosing intimate relationships among clotting, fibrinolysis and kinin generation which may be viewed as body’s defense reactions against injury. This review mainly reflects our research on Fletcher trait and Fitzgerald trait during the 1970s in Cleveland.

Keywords

Contact factor - kinin system - fibrinolysis - Fletcher trait - Fitzgerald trait
 

  • References

  • 1 Margolis J. Glass surface and blood coagulation. Nature 1956; 178: 805-806.
    PubMedGoogle Scholar
  • 2 Shafrir E, de Vries A. Studies on the clot-promoting activity of glass. J Clin Invest 1956; 35: 1183-1190.
    CrossrefPubMedGoogle Scholar
  • 3 Ratnoff OD, Colopy JE. A familiar hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest. 1955; 34: 602-613.
    CrossrefPubMedGoogle Scholar
  • 4 Margolis J. Activation of plasma by contact with glass: Evidence for a common reaction which releases plasma kinin and initiates coagulation. J Physiol. 1958; 144: 1-22.
    PubMedGoogle Scholar
  • 5 Armstrong D, Jepson JB, Keele CA. et al. Pain-producing substance in human inflammatory exudates and plasma. J Physiol 1957; 135: 350-370.
    CrossrefPubMedGoogle Scholar
  • 6 Hathaway WE, Belhasen LP, Hathaway HS. Evidence for a new plasma thromboplastin factor. 1. Case report, coagulation studies, and physicochemical properties. Blood 1965; 26: 521-532.
    PubMedGoogle Scholar
  • 7 Hathaway WE. Discovery of the Fletcher factor: 1963–1965. Ann Rep Hemophilia Thromb Res Soc 2007; 3-4.
    PubMedGoogle Scholar
  • 8 Hathaway WE, Alsever J. The relation of ‘Fletcher Factor’ to Factors XI and XII. Br J Haematol 1970; 18: 161-169.
    CrossrefPubMedGoogle Scholar
  • 9 Saito H, Ratnoff OD, Marshall JS. et al. Partial purification of plasma thromboplastin antecedent (factor XI) and its activation by trypsin. J Clin Invest 1973; 52: 850-861.
    CrossrefPubMedGoogle Scholar
  • 10 Saito H, Ratnoff OD, Donaldson VH. et al. Fletcher factor deficiency (Letter to the Editor). Blood 1972; 39: 745-747.
    PubMedGoogle Scholar
  • 11 Ratnoff OD, Rsenblum JM. Role of Hageman factor in the initiation of clotting by glass. Evidence that glass frees Hageman factor from inhibition. Am J Med 1958; 25: 160-168.
    CrossrefPubMedGoogle Scholar
  • 12 Wuepper KD. Prekallikrein deficiency in man. J Exp Med. 1973; 138: 1345-1355.
    CrossrefPubMedGoogle Scholar
  • 13 Saito H., Ratnoff O.D., Donaldson V.H.. Defective activation of clotting, fibrinolytic, and permeability-enhancing systems in human Fletcher trait plasma. Circ Res 1974; 34: 641-651.
    CrossrefPubMedGoogle Scholar
  • 14 Donaldson V.H., Saito H., Ratnoff O.D.. Defective esterase and kinin-forming activity in human Fletcher trait plasma; a fraction rich in kallikrein-like activity. Circ Res 1974; 34: 652-662.
    CrossrefPubMedGoogle Scholar
  • 15 Weiss AS, Gallin JI, Kaplan AP. Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J Clin Invest 1974; 53: 622-633.
    CrossrefPubMedGoogle Scholar
  • 16 Saito H., Ratnoff O.D.. Inhibition of normal clotting and Fletcher factor activity by rabbit anti-kallikrein antiserum. Nature (London) 1974; 248: 597-598.
    CrossrefPubMedGoogle Scholar
  • 17 Waldmann R., Abraham J.P., Rebuck J.W.. et al. Fitzgerald factor: a hitherto unrecognized coagulation factor. Lancet 1975; 01: 949-952.
    PubMedGoogle Scholar
  • 18 Saito H., Ratnoff O.D., Waldmann R.. et al. Fitzgerald trait: Deficiency of a hitherto unrecognized agent, Fitzgerald factor, participating in surface-mediated reactions of clotting, fibrinolysis and generation of kinins and PE/Dil. J Clin Invest 1975; 55: 1082-1089.
    CrossrefPubMedGoogle Scholar
  • 19 Schiffman S, Lee P. Preparation, characterization, and activation of a highly purified Factor XI: Evidence that a hitherto unrecognized plasma activity participates in the interaction of Factors XI and XII. Br J Haematol 1974; 27: 101-114.
    CrossrefPubMedGoogle Scholar
  • 20 Schiffman S, Lee P, Waldmann R. Identity of contact activation co-factor with Fitzgerald factor. Thromb Res 1975; 06: 451-4.
    CrossrefPubMedGoogle Scholar
  • 21 Jacobsen S. Separation of two different substrates for plasma kinin-forming enzymes. Nature (Lond.) 1966; 210: 98-99.
    CrossrefPubMedGoogle Scholar
  • 22 Lacombe M-J, Varet B, Levy J-P. A hitherto undescribed plasma factor activity at the contact phase of blood coagulation (Flaujeac factor): Case report and coagulation studies. Blood 1975; 46: 761-768.
    PubMedGoogle Scholar
  • 23 Wuepper KD, Miller D, Lacombe M. Flaujeac trait. Deficiency of human plasma kininogen. J Clin Invest 1975; 56: 1663-1672.
    CrossrefPubMedGoogle Scholar
  • 24 Colman RW, Bagdasarian A, Talamo RC. et al. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 1975; 56: 1650-1662.
    CrossrefPubMedGoogle Scholar
  • 25 Donaldson VH, Glueck HI, Miller A. et al. Kininogen deficiency in Fitzgerald trait: role of high molecular weight kininogen in clotting and fibrinolysis. J Lab Clin Med 1976; 87: 327-337.
    PubMedGoogle Scholar
  • 26 Lutcher CL. Reid trait: A new expression of high molecular weight kininogen (HMW kininogen) deficiency. Clin Res 1976; 24: 47A.
    PubMedGoogle Scholar
  • 27 Saito H.. Purification of HMW-kininogen (Fitzgerald factor) and the role of this agent in blood coagulation. J Clin Invest 1977; 60: 584-594.
    CrossrefPubMedGoogle Scholar
  • 28 Griffin JH. Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc Natl Acad Sci USA 1978; 75: 1998-2002.
    CrossrefPubMedGoogle Scholar
  • 29 Cochrane CG, Revak SD, Wuepper KD. Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein. J Exp Med 1973; 138: 1564-1583.
    CrossrefPubMedGoogle Scholar
  • 30 Mandel R, Colman RW, Kaplan A. Identification of prekallikrein and high molecular weight kininogen as a complex in human plasma. Proc Natl Acad Sci USA 1976; 73: 4179-4183.
    CrossrefPubMedGoogle Scholar
  • 31 Donaldson V.H., Kleniewski J., Saito H.. et al. Prekallikrein deficiency in a kindred with kininogen deficiency and Fitzgerald trait clotting defect : Evidence that high molecular weight kininogen and prekallikrein exist as a complex in normal human plasma. J Clin Invest 1977; 60: 571-583.
    CrossrefPubMedGoogle Scholar
  • 32 Griffin J, Cochrane CG. Mechanisms for the involvement of high M. W. kininogen in surface dependent reaction of Hageman factor. Proc Natl Acad Sci USA 1976; 73: 2554-2558.
    CrossrefPubMedGoogle Scholar
  • 33 Wiggins RC, Bouma BN, Cochrane CG. et al. Role of high-molecular-weight-kininogen in surface-binding and activation of coagulation factor XI and prekallikrein. Proc Natl Acad Sci USA 1977; 74: 4636-4640.
    CrossrefPubMedGoogle Scholar
  • 34 Saito H, Kojima T. Factor XII prekallikrein, and high molecular weight kininogen. In: Molecular Basis of Thrombosis and Hemostasis. Marcel Dekker, Inc.; 1995. pp. 269-285.
    Google Scholar
  • 35 McMillin CR, Saito H, Ratnoff OD. et al. The secondary structure of human Hageman factor (Factor XII) and its alteration by activating agents. J Clin Invest 1974; 54: 1312-1322.
    CrossrefPubMedGoogle Scholar
  • 36 Fair BD, Saito H, Ratnoff OD. et al. Detection by fluorescence of structural changes accompanying the activation of Hageman Factor (Factor XII). Proc Soc Exp Biol Med 1977; 155: 199-202.
    CrossrefPubMedGoogle Scholar
  • 37 Samuel M, Pixley RA, Villanueva MA. et al. Human Factor XII (Hageman factor) autoactivation by dextran sulfate. J Biol Chem 1992; 267: 19691-19697.
    CrossrefPubMedGoogle Scholar
  • 38 Rebuck J, Waldmann R, Abraham J. et al. Importance of contact activated coagulation factors in inflammation. J Reticuloend Soc 1976; 20: 58A.
    PubMedGoogle Scholar
  • 39 Hathaway WE, Wuepper KD, Weston WL. et al. Clinical and physiologic studies of two siblings with prekallikrein (Fletcher factor) deficiency. Am J Med 1976; 60: 654-664.
    CrossrefPubMedGoogle Scholar
  • 40 Poon M-C, Moore MR, Castleberry RP. et al. Severe Fletcher factor (plasma prekallikrein) deficiency with partial deficiency of Hageman factor (Factor XII): Report of a case with observation on in vivo and in vitro leukocyte chemotaxis. Am J Hematol 1982; 12: 261-270.
    CrossrefPubMedGoogle Scholar
  • 41 Ratnoff OD. Some relationships among hemostasis, fibrinolytic phenomena, immunity, and the inflammatory response. In: Advances in Immunology. Vol 10. New York: Academic Press; 1969. pp. 145-227.
    Google Scholar
  • 42 Fujikawa K, Chung DW, Hendrickson LE. et al. Amino acid sequence of human factor XIa blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. Biochemistry 1986; 25: 2417-2424.
    CrossrefPubMedGoogle Scholar
  • 43 Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately?. Blood 2009; 114: 2367-2374.
    CrossrefPubMedGoogle Scholar
  • 44 Alving BM, Hojima Y, Pisano JJ. et al. Hypotension associated with prekallikrein activator (Hageman-factor fragments) in plasma protein fractions. New Eng J Med 1978; 299: 66-77.
    CrossrefPubMedGoogle Scholar
  • 45 Kishimoto TK, Viswanathan K, Ganguly T. et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. New Eng J Med 2008; 358: 2457-2467.
    CrossrefPubMedGoogle Scholar
  • 46 Saito H, Poon M.C., Vicic W., Goldsmith G.H., Menitove J.E.. Human plasma prekallikrein (Fletcher factor) clotting activity and antigen in health and disease. J Lab Clin Med 1978; 92: 84-95.
    PubMedGoogle Scholar
  • 47 Saito H, Goldsmith G, Waldmann R. Fitzgerald factor (high molecular weight kininogen) clotting activity in human plasma in heath and disease, and in various animal plasmas. Blood 1976; 48: 941-947.
    PubMedGoogle Scholar
  • 48 Schapira M, Silver LD, Scott CF. et al. Prekallikrein activation and high molecular weight kininogen consumption in hereditary angioedema. New Eng J Med 1983; 308: 1050-1053.
    CrossrefPubMedGoogle Scholar
  • 49 Blat Y, Seiffert D. A renaissance for the contact system in blood coagulation?. Throm Haemost 2008; 99: 457-460.
    PubMedGoogle Scholar
  • 50 Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 2002; 277: 17962-17969.
    CrossrefPubMedGoogle Scholar
  • 51 Smith SA, Mutch NJ, Baskar D. et al. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 2006; 103: 903-908.
    CrossrefPubMedGoogle Scholar
  • 52 Kannemeier C, Shibamiya A, Nakazawa F. et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 2007; 104: 6388-6393.
    CrossrefPubMedGoogle Scholar
  • 53 Maas C, Govers-Riemslag JWP, Bouma B. et al. Misfolded proteins activate Factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008; 118: 3208-3218.
    PubMedGoogle Scholar
  • 54 Renne T, Pozgaiova M, Gruner S. et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-281.
    CrossrefPubMedGoogle Scholar
  • 55 Merkulov S, Zhang W-M, Komar AA. et al. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. Blood 2008; 111: 1274-1281.
    PubMedGoogle Scholar